Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.41 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL590198 | 0.99 | S1PR1 (0.58) | S1PR1S1PR3RARBTNNC1SGPL1 | |
| SCHEMBL591334 | 0.89 | S1PR1 (0.58) | S1PR1S1PR3RARB | |
| SCHEMBL591335 | 0.89 | S1PR1 (0.56) | S1PR1S1PR3RARB | |
| SCHEMBL10168161 | 0.88 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL589369 | 0.81 | S1PR1 (0.58) | S1PR1S1PR3 | |
| SCHEMBL588792 | 0.81 | S1PR1 (0.76) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL565320 | 0.78 | S1PR1 (0.60) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL19651379 | 0.77 | LMNA (0.47) | RARB | |
| SCHEMBL590838 | 0.76 | S1PR1 (0.75) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL590675 | 0.76 | S1PR1 (0.48) | S1PR1S1PR3TNNC1SGPL1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | ADRB2, ADRB1, ADRB3 | S1PR1 843/4885S1PR3 583/4885RARB 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.